VanEck Pharmaceutical ETF (NYSEARCA:PPH) exists to give investors broad exposure to the global pharmaceutical industry without the binary risk of betting on a single drug pipeline. Right now, that ...

“PPH requests appear to have been filed for less than 1% of U.S. applications. Why are applicants foregoing the program? While the program does not require payment of a fee per se, the author proposes ...

VanEck Pharmaceutical ETF offers focused exposure to large-cap pharmaceutical companies, benefiting from strong long-term demographic and innovation trends. PPH's high concentration in top holdings ...

VanEck Pharmaceutical ETF has had the strongest one-year performance of four major pharmaceutical ETF competitors due to its unique mix of Novo Nordisk, Eli Lilly, and Johnson & Johnson. Eli Lilly, ...

Looking for broad exposure to the Healthcare - Pharma segment of the equity market? You should consider the VanEck Pharmaceutical ETF (PPH), a passively managed exchange traded fund launched on ...

Below is Validea's ETF fundamental report for VanEck Pharmaceutical ETF (PPH). The report looks at PPH's exposure to the major investing factors including value, quality, momentum and low volatility.

Beginning in July 2006, the United States Patent and Trademark Office (USPTO) has partnered with several other offices in Patent Prosecution Highway (PPH) programs. As of the end of fiscal year 2016, ...

Noah has about a year of writing experience. He's worked on his investing website dealing with topics such as the stock market and financial advice for beginners. Pharmaceutical exchange-traded funds ...